Ganesh Raghu

List of Publications by Citations

204 papers	32,835 citations	73 h-index	181 g-index
239 ext. papers	41,232 ext. citations	12.6 avg, IF	7.02 L-index

#	Paper	IF	Citations
204	An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 788-824	10.2	4665
203	Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *New England Journal of Medicine*, **2014**, 370, 2071-82	59.2	2337
202	An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 733-48	10.2	2176
201	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, e44-e68	10.2	1426
200	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, e3-19	10.2	1122
199	Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. *New England Journal of Medicine*, **2012**, 366, 1968-77	59.2	992
198	Incidence and prevalence of idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 174, 810-6	10.2	916
197	Acute exacerbations of idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 176, 636-43	10.2	823
196	Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. *New England Journal of Medicine*, **2011**, 365, 1079-87	59.2	728
195	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 265-75	10.2	653
194	An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 1004-14	10.2	593
193	A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. *New England Journal of Medicine*, **2004**, 350, 125-33	59.2	545
192	Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. *New England Journal of Medicine*, **2019**, 380, 2518-2528	59.2	532
191	Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 170, 904-10	10.2	450
190	Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **1998**, 158, 1804-8	10.2	430
189	The clinical course of patients with idiopathic pulmonary fibrosis. *Annals of Internal Medicine*, **2005**, 142, 963-7	8	423
188	BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 177, 75-81	10.2	407

187	Idiopathic pulmonary fibrosis. *Nature Reviews Disease Primers*, **2017**, 3, 17074	51.1	395
186	Telomere shortening in familial and sporadic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 729-37	10.2	379
185	Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. *American Journal of Respiratory and Critical Care Medicine*, **1999**, 159, 1061-9	10.2	378
184	High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 172, 488-93	10.2	373
183	Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. *Lancet Respiratory Medicine,the*, **2014**, 2, 566-72	35.1	348
182	Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. *New England Journal of Medicine*, **2014**, 370, 2093-101	59.2	343
181	An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. *European Respiratory Journal*, **2014**, 44, 1479-503	13.6	338
180	BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 184, 92-9	10.2	333
179	Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. *Annals of Internal Medicine*, **2013**, 158, 641-9	8	327
178	Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. *The American Review of Respiratory Disease*, **1991**, 144, 291-6		326
177	The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study. *Chest*, **1999**, 116, 1168-74	5.3	322
176	Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 184, 459-66	10.2	294
175	Rheumatoid arthritis-interstitial lung disease-associated mortality. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 372-8	10.2	289
174	Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. *Lancet Respiratory Medicine,the*, **2013**, 1, 369-76	35.1	276
173	Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 948-55	10.2	269
172	Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 680-689	10.2	238
171	Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. *European Respiratory Journal*, **2015**, 46, 1113-30	13.6	218
170	Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. *Lancet Respiratory Medicine,the*, **2013**, 1, 685-94	35.1	214

169	Assessment of health-related quality of life in patients with interstitial lung disease. *Chest*, **1999**, 116, 1175-82	5.3	210
168	Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 175, 1054-60	10.2	190
167	TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 1475-82	10.2	187
166	Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. *Chest*, **2005**, 127, 171-7	5.3	181
165	Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. *Chest* , **2006**, 129, 794-800	5.3	177
164	Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, e36-e69	10.2	175
163	The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. *Respiratory Medicine*, **2010**, 104, 296-304	4.6	167
162	Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. *European Respiratory Journal*, **2013**, 42, 1622-32	13.6	166
161	Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 1044-8	10.2	165
160	Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. *European Respiratory Journal*, **2016**, 48, 1710-1720	13.6	164
159	An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. *Journal of Rheumatology*, **2016**, 43, 1672-9	4.1	163
158	Does chronic microaspiration cause idiopathic pulmonary fibrosis?. *American Journal of Medicine*, **2010**, 123, 304-11	2.4	156
157	Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old. *European Respiratory Journal*, **2016**, 48, 179-86	13.6	154
156	Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. *Lancet Respiratory Medicine,the*, **2017**, 5, 22-32	35.1	142
155	Rheumatoid arthritis-associated lung disease. *European Respiratory Review*, **2015**, 24, 1-16	9.8	135
154	Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. *Lancet Respiratory Medicine,the*, **2014**, 2, 277-84	35.1	135
153	Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. *New England Journal of Medicine*, **2018**, 379, 1722-1731	59.2	135
152	Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. *Lancet Respiratory Medicine,the*, **2020**, 8, 171-181	35.1	131

151	Differential proliferation of fibroblasts cultured from normal and fibrotic human lungs. *The American Review of Respiratory Disease*, **1988**, 138, 703-8		130
150	Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. *European Respiratory Journal*, **2014**, 44, 1296-307	13.6	126
149	Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis. *Chest*, **2016**, 149, 756-66	5.3	112
148	FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2016**, 47, 1481-91	13.6	112
147	Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 78-85	10.2	108
146	Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2018**, 319, 2299-2307	27.4	107
145	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1249-1254	10.2	105
144	Elevated transforming growth factor-alpha levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. *American Journal of Respiratory and Critical Care Medicine*, **1998**, 158, 424-30	10.2	104
143	Interstitial Lung Disease: A Diagnostic Approach: Are CT Scan and Lung Biopsy Indicated in Every Patient?. *American Journal of Respiratory and Critical Care Medicine*, **1995**, 151, 909-914	10.2	101
142	Interstitial Lung Disease in India. Results of a Prospective Registry. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 801-813	10.2	91
141	Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. *European Respiratory Journal*, **2015**, 46, 1370-7	13.6	88
140	Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. *Lancet Respiratory Medicine,the*, **2015**, 3, 473-82	35.1	81
139	Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet Respiratory Medicine,the*, **2020**, 8, 25-33	35.1	81
138	Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. *Journal of Translational Medicine*, **2015**, 13, 249	8.5	79
137	Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?. *Lancet Respiratory Medicine,the*, **2018**, 6, 154-160	35.1	76
136	First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value. *Lung*, **2016**, 194, 739-43	2.9	76
135	Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. *Lancet Respiratory Medicine,the*, **2018**, 6, 707-714	35.1	74
134	High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study. *European Respiratory Journal*, **2016**, 48, 1442-1452	13.6	74

133	CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. *European Respiratory Journal*, **2015**, 46, 1740-50	13.6	64
132	Symptomatic Respiratory Virus Infection and Chronic Lung Allograft Dysfunction. *Clinical Infectious Diseases*, **2016**, 62, 313-319	11.6	64
131	Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older. *Annals of the American Thoracic Society*, **2015**, 12, 981-7	4.7	63
130	Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. *European Respiratory Journal*, **2017**, 50,	13.6	61
129	Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. *Lancet Respiratory Medicine,the*, **2019**, 7, 487-496	35.1	61
128	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. *Lancet Respiratory Medicine,the*, **2015**, 3, 388-96	35.1	57
127	Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. *Chest*, **2011**, 139, 441-443	5.3	57
126	Idiopathic Pulmonary Fibrosis: Novel Concepts of Proton Pump Inhibitors as Antifibrotic Drugs. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 193, 1345-52	10.2	57
125	Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. *European Respiratory Review*, **2019**, 28,	9.8	56
124	Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. *BMC Medicine*, **2016**, 14, 18	11.4	54
123	Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning. *Annals of the American Thoracic Society*, **2017**, 14, 1646-1654	4.7	54
122	COVID-19 interstitial pneumonia: monitoring the clinical course in survivors. *Lancet Respiratory Medicine,the*, **2020**, 8, 839-842	35.1	53
121	The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. *Lancet Respiratory Medicine,the*, **2017**, 5, 61-71	35.1	52
120	Air pollution and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA) air-lung study. *European Respiratory Journal*, **2017**, 50,	13.6	51
119	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *European Respiratory Journal*, **2017**, 50,	13.6	50
118	The role of gastroesophageal reflux in idiopathic pulmonary fibrosis. *American Journal of Medicine*, **2003**, 115 Suppl 3A, 60S-64S	2.4	50
117	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). *European Respiratory Review*, **2020**, 29,	9.8	50
116	Interstitial lung disease: clinical evaluation and keys to an accurate diagnosis. *Clinics in Chest Medicine*, **2004**, 25, 409-19, v	5.3	48

115	A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. *Chest*, **2018**, 153, 94-104	5.3	47
114	Rheumatoid arthritis-associated autoantibodies and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. *Thorax*, **2016**, 71, 1082-1090	7.3	43
113	Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. *Lancet Respiratory Medicine,the*, **2019**, 7, 657-664	35.1	42
112	High-Attenuation Areas on Chest Computed Tomography and Clinical Respiratory Outcomes in Community-Dwelling Adults. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1434-1442	10.2	41
111	Hypersensitivity Pneumonitis: Current Concepts of Pathogenesis and Potential Targets for Treatment. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 301-308	10.2	41
110	Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 336-347	10.2	41
109	SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772). *European Respiratory Journal*, **2018**, 52,	13.6	41
108	Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre. *European Respiratory Journal*, **2016**, 48, 826-32	13.6	39
107	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. *Lancet Respiratory Medicine,the*, **2021**, 9, 96-106	35.1	38
106	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.. *American Journal of Respiratory and Critical Care Medicine*, **2022**, 205, e18-e47	10.2	38
105	Current approaches to the management of idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2017**, 129, 24-30	4.6	37
104	Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year. *Chest*, **2017**, 152, 103-112	5.3	35
103	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. *European Respiratory Journal*, **2015**, 46, 243-9	13.6	35
102	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1146-1153	10.2	33
101	Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter. *Chest*, **2009**, 136, 16-22	5.3	33
100	Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2018**, 52,	13.6	30
99	Pulmonary arteriovenous malformations: an uncharacterised phenotype of dyskeratosis congenita and related telomere biology disorders. *European Respiratory Journal*, **2017**, 49,	13.6	29
98	Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. *BMC Pulmonary Medicine*, **2020**, 20, 3	3.5	29

97	Occupational Exposures and Subclinical Interstitial Lung Disease. The MESA (Multi-Ethnic Study of Atherosclerosis) Air and Lung Studies. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1031-1039	10.2	28
96	Telemedicine - maintaining quality during times of transition. *Nature Reviews Disease Primers*, **2020**, 6, 45	51.1	27
95	Smoking-related idiopathic interstitial pneumonia. *European Respiratory Journal*, **2014**, 44, 594-602	13.6	27
94	Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS trials. *Respiratory Research*, **2018**, 19, 167	7.3	27
93	Lung transplantation in idiopathic pulmonary fibrosis. *Expert Review of Respiratory Medicine*, **2018**, 12, 375-385	3.8	26
92	Pneumocystis carinii pneumonia associated with profound lymphopenia and abnormal T-lymphocyte subset ratios during treatment for early-stage breast carcinoma. *Cancer*, **1991**, 67, 2407-9	6.4	25
91	Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers. *Chest*, **2018**, 154, 1359-1370	5.3	25
90	Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging. *International Journal of Cardiology*, **2017**, 241, 457-462	3.2	24
89	Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. *Chest*, **2014**, 146, 1256-1262	5.3	24
88	Idiopathic pulmonary fibrosis: current trends in management. *Clinics in Chest Medicine*, **2004**, 25, 621-36, v	5.3	23
87	Interstitial pneumonia with autoimmune features: the new consensus-based definition for this cohort of patients should be broadened. *European Respiratory Journal*, **2016**, 47, 1293-5	13.6	23
86	Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential. *European Respiratory Review*, **2017**, 26,	9.8	22
85	Human lung fibroblast subpopulations with different C1q binding and functional properties. *American Journal of Respiratory Cell and Molecular Biology*, **1992**, 6, 382-9	5.7	21
84	Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?. *Respiratory Medicine*, **2018**, 144S, S20-S27	4.6	21
83	A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis. *Chest*, **2020**, 158, 637-645	5.3	20
82	Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design. *Chest*, **2015**, 148, 1083-1092	5.3	20
81	Lung function outcomes in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2019**, 146, 42-48	4.6	20
80	Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 211-220	10.2	20

79	Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA. *European Respiratory Journal*, **2018**, 52,	13.6	20
78	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. *Chest*, **2020**, 157, 1506-1512	5.3	18
77	Bronchoalveolar Lavage Lymphocytes in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease. *Annals of the American Thoracic Society*, **2020**, 17, 1455-1467	4.7	17
76	Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. *European Respiratory Review*, **2021**, 30,	9.8	16
75	Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study. *Thorax*, **2017**, 72, 472-474	7.3	15
74	Treatment of Idiopathic Pulmonary Fibrosis. *Annals of the American Thoracic Society*, **2016**, 13, 115-7	4.7	15
73	Identification of usual interstitial pneumonia pattern using RNA-Seq and machine learning: challenges and solutions. *BMC Genomics*, **2018**, 19, 101	4.5	15
72	Fibrotic interstitial lung diseases and air pollution: a systematic literature review. *European Respiratory Review*, **2020**, 29,	9.8	14
71	Hypersensitivity pneumonitis and its correlation with ambient air pollution in urban India. *European Respiratory Journal*, **2019**, 53,	13.6	14
70	Nicotine Modulates Growth Factors and MicroRNA to Promote Inflammatory and Fibrotic Processes. *Journal of Pharmacology and Experimental Therapeutics*, **2019**, 368, 169-178	4.7	13
69	Cardiac sarcoidosis: Diagnosis confirmation by bronchoalveolar lavage and lung biopsy. *Respiratory Medicine*, **2018**, 144S, S13-S19	4.6	13
68	N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open. *Lancet Respiratory Medicine,the*, **2017**, 5, e1-e2	35.1	12
67	Invasive Hemodynamics and Rejection Rates in Patients With Cardiac Sarcoidosis After Heart Transplantation. *Canadian Journal of Cardiology*, **2018**, 34, 978-982	3.8	12
66	Idiopathic pulmonary fibrosis: new evidence and an improved standard of care in 2012. *Lancet, The*, **2012**, 380, 699-701	40	12
65	Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2021**, 325, 1841-1851	27.4	12
64	Idiopathic pulmonary fibrosis: unmasking cryptogenic environmental factors. *European Respiratory Journal*, **2019**, 53,	13.6	12
63	Cryobiopsy for Identification of Usual Interstitial Pneumonia and Other Interstitial Lung Disease Features. Further Lessons from COLDICE, a Prospective Multicenter Clinical Trial. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 1306-1313	10.2	12
62	2018 Clinical Practice Guideline Summary for Clinicians: Diagnosis of Idiopathic Pulmonary Fibrosis. *Annals of the American Thoracic Society*, **2019**, 16, 285-290	4.7	12

61	Epidemiology, survival, incidence and prevalence of idiopathic pulmonary fibrosis in the USA and Canada. *European Respiratory Journal*, **2017**, 49,	13.6	11
60	Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study. *BMJ Open Respiratory Research*, **2019**, 6, e000443	5.6	11
59	Cryobiopsy for Interstitial Lung Disease: The Heat Is On. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 1183-1184	10.2	10
58	Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. *Scientific Reports*, **2019**, 9, 14802	4.9	10
57	Idiopathic Pulmonary Fibrosis Guideline Recommendations. Need for Adherence to Institute of Medicine Methodology?. *Annals of the American Thoracic Society*, **2019**, 16, 681-686	4.7	10
56	Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials. *European Respiratory Journal*, **2019**, 53,	13.6	10
55	Risk factors for disease progression in idiopathic pulmonary fibrosis. *Thorax*, **2020**, 75, 78-80	7.3	10
54	Associations of Serum Adipokines With Subclinical Interstitial Lung Disease Among Community-Dwelling Adults: The Multi-Ethnic Study of Atherosclerosis (MESA). *Chest*, **2020**, 157, 580-589	5.3	9
53	Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of Atherosclerosis. *Respiratory Medicine*, **2018**, 140, 108-114	4.6	8
52	The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. *Annals of the American Thoracic Society*, **2020**, 17, 1620-1628	4.7	8
51	Associations of Β Fatty Acids With Interstitial Lung Disease and Lung Imaging Abnormalities Among Adults. *American Journal of Epidemiology*, **2021**, 190, 95-108	3.8	8
50	Circulating adhesion molecules and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. *European Respiratory Journal*, **2019**, 54,	13.6	7
49	Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study. *ERJ Open Research*, **2020**, 6,	3.5	7
48	Reference values for high attenuation areas on chest CT in a healthy, never-smoker, multi-ethnic sample: The MESA study. *Respirology*, **2020**, 25, 855-862	3.6	6
47	Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?. *BMC Medicine*, **2016**, 14, 22	11.4	6
46	Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications. *Expert Review of Respiratory Medicine*, **2016**, 10, 699-711	3.8	6
45	The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. *Current Neuropharmacology*, **2021**, 19, 1202-1224	7.6	6
44	Pleuroparenchymal fibroelastosis associated with telomerase reverse transcriptase mutations. *European Respiratory Journal*, **2017**, 49,	13.6	5

43	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. *New England Journal of Medicine*, **2020**, 382, 779-780	59.2	5
42	Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution. *Lancet Respiratory Medicine,the*, **2016**, 4, e46-e47	35.1	5
41	Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review. *European Respiratory Review*, **2021**, 30,	9.8	5
40	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial. *American Journal of Respiratory and Critical Care Medicine*, **2021**,	10.2	5
39	Questionnaires or Serum Immunoglobulin G Testing in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease. *Annals of the American Thoracic Society*, **2021**, 18, 130-147	4.7	5
38	The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. *ERJ Open Research*, **2021**, 7,	3.5	5
37	Transbronchial Biopsy and Cryobiopsy in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease. *Annals of the American Thoracic Society*, **2021**, 18, 148-161	4.7	5
36	Hypersensitivity Pneumonitis and (Idiopathic) Pulmonary Fibrosis Due to Feather Duvets and Pillows. *Archivos De Bronconeumologia*, **2021**, 57, 87-93	0.7	5
35	Reply: "The ILD-India Registry: Ignoratio Elenchi" and "The ILD-India Registry: Look Before You Leap". *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 837-839	10.2	4
34	Idiopathic pulmonary fibrosis: combating on a new turf. *Lancet Respiratory Medicine,the*, **2016**, 4, 430-2	35.1	4
33	Lung transplantation for interstitial lung disease. *European Respiratory Review*, **2021**, 30,	9.8	4
32	Cryptogenic organising pneumonia: current understanding of an enigmatic lung disease. *European Respiratory Review*, **2021**, 30,	9.8	4
31	Idiopathic pulmonary fibrosis: shifting the concept to irreversible pulmonary fibrosis of many entities. *Lancet Respiratory Medicine,the*, **2019**, 7, 926-929	35.1	3
30	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). *Lung India*, **2020**, 37, 359	1.1	3
29	Regional distribution of high-attenuation areas on chest computed tomography in the Multi-Ethnic Study of Atherosclerosis. *ERJ Open Research*, **2020**, 6,	3.5	3
28	Recurrent Pulmonary Fibrosis in a Lung Allograft Secondary to Antisynthetase Syndrome. *Annals of the American Thoracic Society*, **2020**, 17, 901-904	4.7	3
27	Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. *Journal of Inflammation*, **2021**, 18, 17	6.7	3
26	Diagnosis of idiopathic pulmonary fibrosis by virtual means using "IPFdatabase"- a new software. *Respiratory Medicine*, **2019**, 147, 31-36	4.6	3

25	Diagnosis of Hypersensitivity Pneumonitis in Adults, 2020 Clinical Practice Guideline: Summary for Clinicians. *Annals of the American Thoracic Society*, **2021**, 18, 559-566	4.7	3
24	Hypersensitivity pneumonitis: Clinical manifestations - Prospective data from the interstitial lung disease-India registry. *Lung India*, **2019**, 36, 476-482	1.1	2
23	R-Scale for Pulmonary Fibrosis (PF): a simple, visual tool for the assessment of health-related quality of life. *European Respiratory Journal*, **2021**,	13.6	2
22	Use of a Genomic Classifier in Patients with Interstitial Lung Disease: A Systematic Review. *Annals of the American Thoracic Society*, **2021**,	4.7	2
21	Accuracy of Digital Tomosynthesis of the Chest in Detection of Interstitial Lung Disease Comparison With Digital Chest Radiography. *Journal of Computer Assisted Tomography*, **2019**, 43, 109-114	2.2	2
20	Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.. *Annals of the American Thoracic Society*, **2022**, 19, 833-844	4.7	2
19	Antacid use and subclinical interstitial lung disease: the MESA study. *European Respiratory Journal*, **2017**, 49,	13.6	1
18	Progress in the management of IPF-related acute exacerbations: a goal for patients, respirologists and intensivists. *European Respiratory Journal*, **2018**, 51,	13.6	1
17	Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT--authorsPreply. *Lancet Respiratory Medicine,the*, **2014**, 2, e5-6	35.1	1
16	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). *Lung India*, **2020**, 37, 359-378	1.1	1
15	Associations of D-Dimer with Computed Tomographic Lung Abnormalities, Serum Biomarkers of Lung Injury, and Forced Vital Capacity: MESA Lung Study. *Annals of the American Thoracic Society*, **2021**, 18, 1839-1848	4.7	1
14	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, e3-e23	10.2	1
13	Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. *European Respiratory Journal*, **2021**, 57,	13.6	1
12	Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.. *Annals of the American Thoracic Society*, **2022**,	4.7	1
11	Sarcoidosis and idiopathic pulmonary fibrosis: The same tale or a tale of two diseases in one. *Respiratory Medicine*, **2019**, 160, 105668	4.6	0
10	A Molecular Classifier That Identifies Usual Interstitial Pneumonia in Transbronchial Biopsy Specimens of Patients With Interstitial Lung Disease. *Chest*, **2020**, 157, 1391-1392	5.3	0
9	Methodologies of COLDICE and Cryo-PID studies: details make the difference. *Annals of Translational Medicine*, **2020**, 8, 781	3.2	0
8	Survival predictors of interstitial lung disease in India: Follow-up of Interstitial Lung Disease India registry. *Lung India*, **2021**, 38, 5-11	1.1	0

7	Soluble ECM promotes organotypic formation in lung alveolar model.. *Biomaterials*, **2022**, 283, 121464	15.6	0
6	Antinuclear antibodies and subclinical interstitial lung disease in community-dwelling adults: the MESA study. *European Respiratory Journal*, **2020**, 55,	13.6	
5	In Reply. *Archives of Pathology and Laboratory Medicine*, **2021**, 145, 1326-1327	5	
4	Gastroesophageal Reflux and Idiopathic Pulmonary Fibrosis **2018**, 195-204		
3	Reply to Mor□-Mendoza and Khalil: Are Ground-Glass Opacities on Chest High-Resolution Computed Tomography a Manifestation of Airway Disease?. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 781-782	10.2	
2	Reply to Moodley and to Ravaglia et al. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 667-669	10.2	
1	Response to Letter to Editor regarding "Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?". *Respiratory Medicine*, **2019**, 149, 43-44	4.6	